{
    "Clinical Trial ID": "NCT00393939",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Docetaxel + Sunitinib",
        "  Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib).",
        "INTERVENTION 2: ",
        "  Docetaxel",
        "  Docetaxel 100 mg/m^2 every 3 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Breast cancer with evidence of unresectable locally recurrent, or metastatic disease",
        "  Her-2 negative tumors",
        "Exclusion Criteria:",
        "  Patients for whom docetaxel is contraindicated",
        "  Clinical presentation of inflammatory carcinoma with no other measurable disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival (PFS)",
        "  PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4.",
        "  Time frame: Baseline up to Month 33",
        "Results 1: ",
        "  Arm/Group Title: Docetaxel + Sunitinib",
        "  Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg daily in continuous dosing (in absence of docetaxel), or docetaxel 100 mg/m^2 every 3 weeks (in absence of sunitinib).",
        "  Overall Number of Participants Analyzed: 296",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  Independent radiology assessment: 8.6        (8.2 to 10.3)",
        "  Investigator's assessment: 8.2        (7.3 to 8.6)",
        "Results 2: ",
        "  Arm/Group Title: Docetaxel",
        "  Arm/Group Description: Docetaxel 100 mg/m^2 every 3 weeks",
        "  Overall Number of Participants Analyzed: 297",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  Independent radiology assessment: 8.3        (7.7 to 9.6)",
        "  Investigator's assessment: 6.9        (6.5 to 7.3)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 112/295 (37.97%)",
        "  Anaemia 4/295 (1.36%)",
        "  Febrile neutropenia 20/295 (6.78%)",
        "  Leukopenia 5/295 (1.69%)",
        "  Lymphatic disorder 1/295 (0.34%)",
        "  Neutropenia 11/295 (3.73%)",
        "  Thrombocytopenia 1/295 (0.34%)",
        "  Angina pectoris 0/295 (0.00%)",
        "  Atrial fibrillation 1/295 (0.34%)",
        "  Atrioventricular block 1/295 (0.34%)",
        "  Cardiac arrest 1/295 (0.34%)",
        "  Cardiac disorder 1/295 (0.34%)",
        "Adverse Events 2:",
        "  Total: 79/293 (26.96%)",
        "  Anaemia 2/293 (0.68%)",
        "  Febrile neutropenia 13/293 (4.44%)",
        "  Leukopenia 7/293 (2.39%)",
        "  Lymphatic disorder 0/293 (0.00%)",
        "  Neutropenia 16/293 (5.46%)",
        "  Thrombocytopenia 0/293 (0.00%)",
        "  Angina pectoris 1/293 (0.34%)",
        "  Atrial fibrillation 0/293 (0.00%)",
        "  Atrioventricular block 0/293 (0.00%)",
        "  Cardiac arrest 0/293 (0.00%)",
        "  Cardiac disorder 0/293 (0.00%)"
    ]
}